It is now well established that HIV can escape the immune responses that could otherwise control the infection, including both antibody and T cell responses. The latter has received much attention since it was fi rst proposed in 1991 ( 1 ) , and selection of escape mutations in several HIV epitopes targeted by CD8 + T cells has been carefully documented ( 2 -5 ) . Epitope escape usually occurs early in infection, as the rapidly replicating virus displays almost every possible mutation enabling it to evade any suppressive force. Although such escape mutations often undermine immune control, many also have a fi tness cost for the virus ( 2, 3 ) so that escape is not always bad for the patient.
The fi rst described and best-studied HIV CTL epitope comes from the p24 gag protein and spans amino acids 263 -272 (KRWIILGLNK). This epitope is presented to CD8 + T cells by HLA B27 ( 2, 4 -8 ) . In patients with HLA B27, the CD8 + T cell response is dominated by T cells specifi c for this epitope, probably because these T cells are functionally diverse, bind antigen with relatively high avidity, and proliferate well ( 9 ) . This response appears early in infection 11 ) show that one of the mutations involved in this escape enhances HLA B27 binding to the inhibitory receptor immunoglobulin-like transcript (ILT) molecule 4 (also known as LIR2), which is expressed on monocytes and DCs ( 11 ).
Mechanics of a mutation
Peptides that bind to HLA B27 almost always have an arginine (R) at the second position, which fi ts snugly into the B pocket of the peptide-binding groove of the HLA molecule. The arginine at position 264 in the HIV-1 gag 263 -272 epitope is encoded by the amino acid codon AGA (or more rarely, AGG). Escape can occur when this arginine is mutated. The single mutations that have been recorded at this codon include AAA (lysine), ACA (threonine), and GGA or AGG (glycine). Although peptides with these substitutions may bind suffi ciently to HLA B27 in in vitro assays, they are not recognized by T cells when expressed within the cell as viral or transfected sequences ( 8 ) . These mutations thus eff ectively remove the epitope from the immune response. Given the high replication and mutation rates of HIV-1, one might expect the virus to escape rapidly and completely from the early T cells that recognize this epitope. Escape from this epitope, however, typi cally occurs only after several years, happening in at least 50% of HLA B27 patients who are studied for several years ( 3 , 11 , 12 , and unpublished data). According to the Los Alamos HIV sequence database, these mutations are very rare in the general population of HIVinfected individuals, 95% of whom do not have HLA B27.
A possible explanation for the late escape was provided by Kelleher et al. ( 7 ), who showed that the critical arginine-to-lysine change at position 264 (R264K) only occurred when there had been a pre vious change of leucineto-methionine at position six in the epitope (L268M). Unlike the arginine at position 2, the side chain at position 6 is not involved in HLA B27 binding but rather faces and interacts with the T cell receptor ( Fig. 1 ). More recently, Schneidewind et al. ( 4 ) showed that there is nearly always a third amino acid change that accompanies the R264K and L268M mutations: an alanine-toserine change at position 173 (A173S). This amino acid lies outside the epitope, but the three mu tated amino acids cluster in the three-dimensional structure of p24, suggesting that they might compensate for each other. The R264K mutation imparts a fi tness cost on the virus, as elegantly shown by Goulder et al. ( 2 ), who found that the virus rapidly mutated this sequence back to wild-type in HLA B27 − babies that had been infected by B27 + mothers carrying the mutated virus. This was directly tested in vitro by Schneidewind et al., who showed that an infectivity fi tness cost for the R264K mutation was compensated for by the A173S mutation ( 4 ). This requirement for a triple mutation must be much rarer than a single mutation, and probably accounts for the delayed escape from this T cell response.
Complexity of HIV escape
These observations imply a novel escape mechanism involving the inhibitory ILT4 receptor. This is the fi rst demonstration that mutation in an HIV-1 CTL epitope can contribute to virus escape by infl uencing the interaction between HLA class I and a molecule other than the T cell receptor, although it is known that diff erent epitope peptides (none yet known to escape) can infl uence the interaction between HLA molecules and other inhibitory receptors, such as the KIR family ( 12 ) . This is an important story for understanding HIV infection. The virus must be under considerable immune pressure to select this complex mosaic of mutations (Table I ). Yet ultimately the virus evades immune control with the triple mutation and the virus load rises ( 8 ) .
Because this requires such a long period of time, other factors such as the loss of CD4 T cells must also contribute to the progression to AIDS. However, patients with B27 do progress to disease more slowly than the average HIVinfected individual, possibly because the B27-restricted T cells concentrate wild-type peptide with HLA B27. ILT4 is present on monocytes and DCs, and contains a cytoplasmic ITIM motif that delivers an inhibitory signal to the cell. Thus, the mutant peptide -B27 complex could impair the function of monocytes and DCs. One might expect this to have a negative eff ect on T cell function. The authors show, however, that after the L268M mutation occurs, a vigorous new primary T cell response develops against the new epitope. This fact is diffi cult to square with impaired DC function, but the authors provide a potential explanation. They show that ILT4 expression on monocytes and DCs is low in early HIV infection and increases as the infection progresses. They argue that if the L268M mutation arises early in the infection, the DCs can still prime new T cell responses, but as the infection progresses and ILT4 expression increases, other new T cell responses may be impaired by the ILT4-mediated inhibition of DCs. This could give the mutant virus a longer-term advantage. It will thus be interesting to compare the breadth of T cell responses late in infection in B27 + patients who do or do not have this epitope mutation.
Mutation disarms DCs
In this issue, Lichterfeld et al. ( 11 ) report a longitudinal study, which shows that the L268M change occurs early in infection, suggesting that it is the fi rst in the sequence of changes that leads to escape, and that the mutation becomes fi xed (Table I) . Fixation implies that the mutation confers some advantage for the virus in the presence of the T cell response. The leucine at this position is likely to interact with the T cell receptor ( Fig. 1 ) , and the initial T cell response tends to be specifi c for the L-containing epitope. This response then drives selection of the M-containing mutant, which in turn stimulates a new cross-reactive T cell response ( 11 ) . Any advantage of the Mcontaining epitope would therefore seem to be transient, but the fact that this mutation persists suggests that it confers some other, as yet unknown, advantage to the virus.
Lichterfeld et al. now give an intriguing insight into what this advantage might be. They show that complexes of the L268M mutant peptide bound to HLA B27 bind to ILT4 with three times higher affi nity than do complexes of the 
